Premier Path Wealth Partners LLC Has $667,000 Holdings in Thermo Fisher Scientific Inc. $TMO

Premier Path Wealth Partners LLC decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,646 shares of the medical research company’s stock after selling 247 shares during the period. Premier Path Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $667,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of TMO. CBIZ Investment Advisory Services LLC raised its position in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific during the first quarter valued at about $30,000. Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at approximately $31,000. IMA Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $35,000. Finally, DiNuzzo Private Wealth Inc. increased its position in shares of Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 61 shares during the period. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Wells Fargo & Company lifted their price target on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Finally, William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating for the company. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Trading Down 0.4%

TMO stock opened at $556.32 on Friday. The business has a fifty day moving average price of $509.50 and a 200 day moving average price of $456.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The stock has a market capitalization of $210.07 billion, a price-to-earnings ratio of 32.14, a P/E/G ratio of 3.27 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the business earned $5.28 earnings per share. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $574.15, for a total transaction of $229,660.00. Following the transaction, the executive vice president owned 21,152 shares of the company’s stock, valued at approximately $12,144,420.80. This represents a 1.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 54,420 shares of company stock worth $28,134,684 in the last quarter. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.